These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15622495)

  • 21. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
    Naganuma A; Toyoda M; Hamada T; Hagiwara S; Yanagisawa M; Kosone T; Arai H; Abe T; Takagi H
    Gan To Kagaku Ryoho; 2007 May; 34(5):729-34. PubMed ID: 17496446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma.
    Tam KH; Yang ZF; Lau CK; Lam CT; Pang RW; Poon RT
    Cancer Lett; 2009 Jan; 273(2):201-9. PubMed ID: 18824293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
    Allgaier HP; Becker G; Blum HE
    Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L; Kubicka S
    Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyprenoic acid in hepatocellular carcinoma.
    Decensi A; Costa A
    N Engl J Med; 1996 Nov; 335(19):1461; author reply 1461-2. PubMed ID: 8927082
    [No Abstract]   [Full Text] [Related]  

  • 28. Liver cancer stem cells: implications for a new therapeutic target.
    Lee TK; Castilho A; Ma S; Ng IO
    Liver Int; 2009 Aug; 29(7):955-65. PubMed ID: 19490415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Basic and clinical study of interferon a in hepatocellular carcinoma].
    Sun HC; Wang L; Wu WZ
    Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1606-8. PubMed ID: 19094750
    [No Abstract]   [Full Text] [Related]  

  • 30. Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy.
    Ferrari D; Di Maria G; Fazio N; Codecà C; Fiore J; Luciani A; Oldani S; Maggioni M; Foa P
    Anticancer Drugs; 2008 Sep; 19(8):837-40. PubMed ID: 18690097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of somatostatin analogs in the management of hepatocellular carcinoma.
    D'Agostino L; Manguso F; Pivonello R; Colao A
    J Endocrinol Invest; 2003; 26(8 Suppl):131-3. PubMed ID: 15233229
    [No Abstract]   [Full Text] [Related]  

  • 32. Embryo extracts opotherapy reduces alpha-fetoprotein levels in hepatocellular carcinoma patients.
    Franchi F; Ielapi T; Bizzarri M; Seminara P
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1467-8. PubMed ID: 16105144
    [No Abstract]   [Full Text] [Related]  

  • 33. 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
    Chuma M; Hige S; Nakanishi M; Ogawa K; Natsuizaka M; Yamamoto Y; Asaka M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1431-6. PubMed ID: 18854000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyprenoic acid in hepatocellular carcinoma.
    Yang CH; Cheng AL
    N Engl J Med; 1996 Nov; 335(19):1460-61; author reply 1461-2. PubMed ID: 8927081
    [No Abstract]   [Full Text] [Related]  

  • 36. Systemic chemotherapy of hepatocellular carcinoma--Korean experience.
    Lee HC
    Oncology; 2008; 75 Suppl 1():114-8. PubMed ID: 19092280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Liu et al.--Estrogen receptor status in inoperable hepatocellular carcinoma.
    Chow PK; Hung H; Soo KC
    Am J Gastroenterol; 2001 Apr; 96(4):1297-8. PubMed ID: 11316190
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting vessels to treat hepatocellular carcinoma.
    Romanque P; Piguet AC; Dufour JF
    Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant hepatoma.
    van Dyk JJ
    Proc Mine Med Off Assoc SA; 1975; 55(421):19-20. PubMed ID: 209446
    [No Abstract]   [Full Text] [Related]  

  • 40. The best candidates for transarterial chemotherapy in patients with hepatocellular carcinoma awaiting liver transplantation: a cohort-based characterization of dropout times.
    Jang JW; Choi JY; Bae SH; Kim CW; Cho SH; Yoon SK; Yang JM; Han JY; Lee YS; Kim DG
    Aliment Pharmacol Ther; 2007 Jul; 26(1):87-94. PubMed ID: 17555425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.